Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| (A)
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
131624182 | 4 | Yes | 0 | 0 | |
| (B)
MEMORIAL HOSPITAL FOR CANCER & ALLIED DISEASES |
131624082 | 3 | Yes | 0 | 0 | |
| (C)
MEMORIAL SLOAN-KETTERING CANCER CENTER |
131924236 | 3 | Yes | 0 | 0 | |
| (D)
LOUIS V GERSTNER JR GRADUATE SCHOOL OF BIOMEDICAL SCIENCES |
202212588 | 2 | Yes | 0 | 0 | |
|
Total 4
|
0 | 0 | ||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 439,291,011 | 446,837,895 | 702,665,000 | 656,514,020 | 686,769,000 | 2,932,076,926 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 439,291,011 | 446,837,895 | 702,665,000 | 656,514,020 | 686,769,000 | 2,932,076,926 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 178,669,532 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 2,753,407,394 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 439,291,011 | 446,837,895 | 702,665,000 | 656,514,020 | 686,769,000 | 2,932,076,926 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 123,653,294 | 88,008,435 | 106,284,504 | 126,987,686 | 121,449,528 | 566,383,447 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | Total support. Add lines 7 through 10 | 3,525,507,808 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 0 | |||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | 0 | |||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | 0 | |||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | 0 | |||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | 0 | |||||
| 6 | Total. Add lines 1 through 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 0 | 0 | 0 | 0 | 0 | 0 |
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | 0 | 0 | 0 | 0 | 0 |
| c | Add lines 7a and 7b.. | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | Public support. (Subtract line 7c from line 6.) | 0 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 0 | 0 | 0 | 0 | 0 | 0 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 0 | |||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | 0 | |||||
| c | Add lines 10a and 10b. | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | 0 | |||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 0 | 0 | 0 | 0 | 0 | 0 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Schedule A, Part I, Line 12g SUPPORTED ORGANIZATIONS | SUPPORT FROM THE SUPPORTING ORGANIZATIONS RELATE PRINCIPALLY TO THE SHARING OF CERTAIN FACILITIES, EQUIPMENT, PERSONNEL COSTS, EDUCATION, INSURANCE AND ALLOCATIONS. AMOUNTS DUE TO OR DUE FROM AFFILIATES RESULTING FROM THESE SERVICES DO NO BEAR INTEREST. |
| Software ID: | 23017437 |
| Software Version: | 2023v5.1 |
| Return Reference | Explanation |
|---|---|
| Schedule E, Part I, Line 3 RACIALLY NONDISCRIMINATORY POLICY | SEE SCHEDULE E, PART II |
| Schedule E, Part I, Line 3 NONDISCRIMINATORY POLICY | THE SCHOOL'S NONDISCRIMINATORY POLICY IS PUBLICIZED ON ITS WEB SITE: HTTPS://WWW.SLOANKETTERING.EDU/GERSTNER/ADMISSIONS/REQUIREMENTS ALL APPLICANTS TO THE LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES ARE CONSIDERED ON THE BASIS OF MERIT. THE SCHOOL DOES NOT DISCRIMINATE ON THE BASIS OF GENDER, RACE, COLOR, CREED, RELIGION, AGE, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS, MARITAL STATUS, SEXUAL ORIENTATION, OR CITIZENSHIP STATUS IN ACCORDANCE WITH INSTITUTIONAL POLICY AND IN COMPLIANCE WITH THE REQUIREMENTS OF THE CIVIL RIGHTS ACT, THE EDUCATION AMENDMENTS, THE REHABILITATION ACT, THE AGE DISCRIMINATION ACT, AND THE AMERICANS WITH DISABILITIES ACT. EXCISE TAX ON NET INVESTMENT INCOME THE LOUIS V GERSTNER JR, GRADUATE SCHOOL OF BIOMEDICAL SCIENCES DOES NOT MEET THE CRITERIA OF SECTION 4968 AND, THEREFORE, IS NOT SUBJECT TO THE EXCISE TAX ON NET INVESTMENT INCOME. |
| Software ID: | 23017437 |
| Software Version: | 2023v5.1 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part III, Line 1 MISSION | THE MISSION OF MEMORIAL SLOAN-KETTERING CANCER CENTER IS TO LEAD IN THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF CANCER AND ASSOCIATED DISEASES THROUGH PROGRAMS OF EXCELLENCE IN RESEARCH, EDUCATION, OUTREACH AND COST-EFFECTIVE PATIENT CARE. LEADERSHIP IN PATIENT CARE: WE PLACE THE HIGHEST PRIORITY ON ADVANCING THE CARE OF CANCER PATIENTS THROUGH EARLY DETECTION, ACCURATE DIAGNOSIS, AND OPTIMAL TREATMENT. THESE THREE ELEMENTS LEAD TO THE MOST EFFECTIVE CANCER CARE POSSIBLE, WHICH IS ALSO THE MOST COST-EFFECTIVE CARE. WE STRIVE FOR EXCELLENCE IN ALL EXISTING AND EMERGING THERAPIES WITHOUT NEGLECTING THE NEED FOR ADVANCED APPROACHES IN PALLIATION. WE DELIVER THESE THERAPIES IN A CARING ENVIRONMENT THAT ENCOMPASSES PATIENTS AS WELL AS THEIR LOVED ONES. EXCELLENCE IN PATIENT CARE IS EXEMPLIFIED BY OUR MULTIDISCIPLINARY APPROACH, A CORE COMPETENCE OF OUR CENTER. WE ARE COMMITTED TO DEVELOPING OUTREACH PROGRAMS TO BRING EXCELLENCE IN CANCER CARE TO THE COMMUNITY. LEADERSHIP IN RESEARCH EXCELLENCE: PATIENT CARE REQUIRES THE EXPEDITIOUS APPLICATION OF NEW KNOWLEDGE DISCOVERED THROUGH RIGOROUS LABORATORY AND CLINICAL RESEARCH. THE INTERRELATIONSHIP BETWEEN SCIENTIFIC DISCOVERY AND ITS APPLICATION TO PATIENT CARE DEFINES OUR UNIQUE NATURE AT ITS BEST. LEADERSHIP IN EDUCATION: TO ENSURE PROGRESS, WE ARE DEDICATED TO PROVIDING THE FINEST EDUCATION AND TRAINING FOR THE MOST PROMISING YOUNG SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE PROFESSIONALS. PUBLIC AND PATIENT EDUCATION ARE ALSO CORNERSTONES FOR PROGRESS AND SUCCESS IN PATIENT CARE, ESPECIALLY IN PREVENTION, EARLY DETECTION, AND COMPLIANCE DURING THERAPY AND MAINTENANCE PROGRAMS. RESOURCES FOR LEADERSHIP: WE ARE STAFFED WITH THE HIGHEST-QUALITY PROFESSIONALS WHO HAVE A FULL-TIME COMMITMENT TO OUR MISSION. WE ARE DETERMINED TO PROVIDE OUR STAFF AND OUR PATIENTS WITH THE FINEST STATE-OF-THE-ART FACILITIES, TECHNOLOGY, MANAGEMENT, AND SUPPORT SERVICES. RESPONSIBILITIES OF LEADERSHIP: MEMORIAL SLOAN-KETTERING CANCER CENTER IS A LEADER IN CANCER RESEARCH AND TREATMENT, OFFERING PATIENTS THE MOST SOPHISTICATED, COMPASSIONATE, AND STATE-OF-THE-ART CARE AVAILABLE AND ADVANCING THE KNOWLEDGE THAT WILL IMPROVE THAT CARE IN THE FUTURE. THE CLOSE COLLABORATION BETWEEN OUR PHYSICIANS AND SCIENTISTS IS ONE OF OUR UNIQUE STRENGTHS, ENABLING US TO PROVIDE PATIENTS WITH THE BEST CARE POSSIBLE AS WE WORK TO DISCOVER MORE-EFFECTIVE STRATEGIES TO PREVENT, CONTROL, AND ULTIMATELY CURE CANCER. |
| Form 990, Part III, Line 4a PATIENT CARE | PATIENT CARE: MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERTS HAVE ESTABLISHED STANDARDS OF CARE AND TREATMENT PROTOCOLS FOR EACH TYPE AND STAGE OF CANCER. OUR PHYSICIANS HAVE AN EXTRAORDINARY DEPTH AND BREADTH OF EXPERIENCE IN DIAGNOSING AND TREATING ALL FORMS OF THE DISEASE, FROM THE MOST COMMON TO THE VERY RARE. EACH YEAR, THEY TREAT MORE THAN 400 DIFFERENT SUBTYPES OF CANCER. THIS LEVEL OF SPECIALIZATION CAN HAVE AN OFTEN-DRAMATIC EFFECT ON A PATIENT'S CHANCES FOR A CURE OR CONTROL OF THEIR CANCER. WHILE WE ARE KNOWN FOR OUR ADVANCED, INNOVATIVE THERAPIES, OUR PHYSICIANS ARE EQUALLY WELL REGARDED FOR THEIR COMPASSION AND CONCERN. OUR DISEASE MANAGEMENT PROGRAM FEATURES 16 MULTIDISCIPLINARY CANCER TEAMS. PATIENTS ARE TREATED BY AS MANY DIFFERENT SPECIALISTS AS ARE NEEDED FOR THEIR PARTICULAR TYPE OF DISEASE, INCLUDING SURGEONS, MEDICAL ONCOLOGISTS, RADIATION ONCOLOGISTS, RADIOLOGISTS, PATHOLOGISTS, PSYCHIATRISTS, AND NURSES. OUR PATHOLOGISTS HAVE UNSURPASSED EXPERTISE IN USING ADVANCED METHODS TO ACCURATELY DIAGNOSE CANCER. BECAUSE OF THEIR SOLE FOCUS ON CANCER, OUR SURGEONS USE SURGICAL TECHNIQUES THAT PRESERVE FORM AND FUNCTION. OUR RADIATION ONCOLOGISTS ARE DEVELOPING AND PUTTING INTO CLINICAL PRACTICE LEADING-EDGE TECHNOLOGIES AND TECHNIQUES IN RADIATION THERAPY. IN ADDITION, THE CENTER OFFERS A FULL RANGE OF PROGRAMS TO HELP PATIENTS AND FAMILIES THROUGHOUT ALL PHASES OF TREATMENT, INCLUDING SUPPORT GROUPS, GENETIC COUNSELING, HELP MANAGING CANCER PAIN AND SYMPTOMS, REHABILITATION, INTEGRATIVE MEDICINE SERVICES, AND ASSISTANCE IN NAVIGATING LIFE AFTER TREATMENT. THROUGHOUT THE COVID-19 PANDEMIC AND BEYOND MSKCC CONTINUES TO WORK TO PROTECT AND ASSIST THE PUBLIC. CURRENTLY, THE INSTITUTION IS ACTIVELY MAINTAINING A POSTURE OF PREVENTION AND SAFETY, WITH ITS EDUCATION PROGRAMS WHILE ENCOURAGING PERSONS TO WEAR THEIR MASKS AND ADHERE TO OTHER PREVENTIVE MEASURES LIKE GETTING BOOSTER SHOTS. |
| Form 990, Part III, Line 4b RESEARCH | RESEARCH: MEMORIAL SLOAN-KETTERING CANCER CENTER MAINTAINS ONE OF THE WORLD'S MOST DYNAMIC PROGRAMS OF CANCER RESEARCH. THE EXTRAORDINARY PATIENT CARE WE PROVIDE BENEFITS FROM OUR INNOVATIVE PROGRAMS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH. RESEARCH AT SLOAN-KETTERING INSTITUTE IS DEDICATED TO UNDERSTANDING THE BIOLOGY OF CANCER THROUGH PROGRAMS IN CELL BIOLOGY, ENETICS, BIOCHEMISTRY, MOLECULAR BIOLOGY, STRUCTURAL BIOLOGY, COMPUTATIONAL BIOLOGY, IMMUNOLOGY, AND THERAPEUTICS. INVESTIGATORS AT SLOAN-KETTERING INSTITUTE COLLABORATE WITH MEMORIAL HOSPITAL PHYSICIAN-SCIENTISTS, A PARTNERSHIP THAT HELPS SPEED IMPORTANT RESEARCH FINDINGS FROM THE LABORATORY TO THE BEDSIDE, IN A PROCESS KNOWN AS TRANSLATIONAL RESEARCH. MEMORIAL SLOAN-KETTERING CANCER CENTER ALSO ACTIVELY INITIATES AND PARTICIPATES IN CLINICAL TRIALS TO IDENTIFY MORE EFFECTIVE CANCER THERAPIES, AND OUR PHYSICIANS ARE CURRENTLY LEADING MORE THAN 1,900 CLINICAL TRIALS FOR PEDIATRIC AND ADULT CANCERS. THE HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM (HOPP) IS A FURTHER EFFORT TO INCREASE INSTITUTIONAL RESEARCH STRENGTH IN AREAS IMPORTANT IN CONTEMPORARY TRANSLATIONAL RESEARCH. HOPP IS DESIGNED TO MELD EVEN MORE THOROUGHLY THE CULTURES OF BASIC BIOLOGIC SCIENCE AND CLINICAL ONCOLOGY, AUGMENTING THE WORK CONDUCTED IN THE LABORATORIES OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S PHYSICIAN-SCIENTISTS. |
| Form 990, Part III, Line 4c EDUCATION | EDUCATION: EDUCATION IS A VITAL PART OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S MISSION. OUR TRAINING PROGRAMS PREPARE PHYSICIANS AND SCIENTISTS FOR CAREERS IN THE BIOMEDICAL SCIENCES. OUR COLLABORATIONS WITH THE ROCKEFELLER UNIVERSITY, CORNELL UNIVERSITY, AND WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY OFFER PHD PROGRAMS IN CHEMICAL BIOLOGY, COMPUTATIONAL BIOLOGY AND MEDICINE, AND THE MEDICAL SCIENCES. THE CENTER ALSO PARTNERS WITH WEILL MEDICAL COLLEGE AND THE ROCKEFELLER UNIVERSITY TO OFFER A MD/PHD DEGREE FOR ASPIRING PHYSICIAN-SCIENTISTS. THE CENTER HAS A PHD PROGRAM IN CANCER BIOLOGY THROUGH ITS LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES. THIS NOVEL PROGRAM HAS BEEN ENROLLING STUDENTS SINCE 2006 AND TRAINS BASIC LABORATORY SCIENTISTS TO WORK IN RESEARCH AREAS DIRECTLY RELEVANT TO CANCER AND OTHER HUMAN DISEASES. WE ALSO OFFER POSTGRADUATE CLINICAL FELLOWSHIPS TO TRAIN PHYSICIANS WHO SEEK SPECIAL EXPERTISE IN A PARTICULAR TYPE OF CANCER AND POSTGRADUATE RESEARCH FELLOWSHIPS THAT PROVIDE PHYSICIANS AND SCIENTISTS WITH ADVANCED LABORATORY RESEARCH TRAINING. WITH FACULTY APPOINTMENTS AT THE WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, OUR CLINICAL STAFF ALSO TRAIN RESIDENTS AND MEDICAL STUDENTS. |
| Form 990, Part VI, Line 15 A & B | MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC) IS COMMITTED TO ENSURING THAT ITS EXECUTIVE COMPENSATION PROGRAM ADHERES TO THE ESTABLISHED STANDARDS OF REGULATORY COMPLIANCE AND BEST CORPORATE GOVERNANCE. THE MSKCC BOARD OF TRUSTEES AND GOVERNING TRUSTEES HAS CHARGED THE JOINT HUMAN RESOURCES COMMITTEE (WHICH IS COMPOSED ENTIRELY OF INDEPENDENT BOARD MEMBERS WITH NO CONFLICTS OF INTEREST IN REGARD TO EXECUTIVE COMPENSATION) WITH MAKING ALL DECISIONS RELATED TO COMPENSATION FOR OFFICERS AND KEY EMPLOYEES. THE COMMITTEE REVIEWS THE TOTAL COMPENSATION OF THE INDIVIDUALS, INCLUDING BOTH CURRENT AND DEFERRED COMPENSATION, AND ALL EMPLOYEE BENEFITS, ON AN ANNUAL BASIS TO ENSURE THAT THE TOTAL COMPENSATION OF EACH OFFICER AND KEY EMPLOYEE IS REASONABLE. TO ASSIST IN THE COMPLETION OF ITS RESPONSIBILITIES, THE COMMITTEE ENGAGES THE SERVICES OF A NATIONALLY RECOGNIZED CONSULTING FIRM SPECIALIZING IN EXECUTIVE COMPENSATION FOR NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS. EACH YEAR THE COMMITTEE REVIEWS A COMPREHENSIVE REPORT PREPARED BY THE FIRM THAT INCLUDES MARKET DATA FOR FUNCTIONALLY COMPARABLE ROLES IN COMPARABLE ORGANIZATIONS (I.E., NOT-FOR-PROFIT ACADEMIC/RESEARCH MEDICAL CENTERS, ESPECIALLY THOSE SHARING A MISSION SIMILAR TO MSKCC, WITH OTHER HEALTHCARE SECTORS CONSIDERED ON A SELECTED BASIS) AND SUMMARIZES THE RELATIVE MARKET POSITION OF EACH EXECUTIVE'S TOTAL COMPENSATION. THE LAST REVIEW WAS MARCH 2023, WHICH SET THE COMPENSATION FOR THE PERIOD APRIL 2023 TO MARCH 2024. ADDITIONALLY, A SENIOR MEMBER OF THE CONSULTING FIRM ATTENDS COMMITTEE MEETINGS TO PROVIDE INFORMATION AND TO RESPOND TO QUESTIONS BY THE MEMBERS OF THE COMMITTEE. COMPENSATION LEVELS ARE ESTABLISHED CONSIDERING THE MARKET DATA, AN ASSESSMENT OF PERFORMANCE, AND OTHER BUSINESS JUDGMENT FACTORS, CONSISTENT WITH MSKCC'S EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE'S DECISIONS ARE MADE IN THE BEST INTERESTS OF MSKCC AND ARE INTENDED TO ENSURE THE RECRUITMENT AND RETENTION OF KEY EXECUTIVE TALENT, CONSISTENT WITH THE MARKET PRACTICES OF OTHER NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS OF COMPARABLE SCOPE, MISSION AND COMPLEXITY. THE COMMITTEE'S REVIEW PROCESS FOLLOWS THE NTERMEDIATE SANCTIONS GUIDELINES FOR QUALIFYING FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE OF 1986: - THE COMPENSATION ARRANGEMENT IS APPROVED IN ADVANCE BY AN "AUTHORIZED BODY" OF THE APPLICABLE TAX EXEMPT ORGANIZATION (I.E, THE COMMITTEE, WHICH IS COMPOSED ENTIRELY OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITHIN THE MEANING OF THE REGULATIONS UNDER SECTION 4958. - THE AUTHORIZED BODY OBTAINS AND RELIES UPON "APPROPRIATE DATA AS TO COMPARABILITY" PRIOR TO MAKING ITS DETERMINATION, FOR WHICH COMPARABILITY DATA ARE PROVIDED AND ANALYZED BY SULLIVAN, COTTER AND ASSOCIATES, INC., A WELL-REGARDED EXPERT IN THE AREA OF HEALTHCARE COMPENSATION. THE COMMITTEE ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION CONCURRENTLY WITH MAKING THAT DETERMINATION, AGAIN AS REQUIRED IN THE REGULATIONS. |
| Form 990, Part VI, Line 2 Family/business relationships amongst interested persons | DIRECTORS ELLEN V. FUTTER AND PETER J. SOLOMON - Business relationship, DIRECTORS ELLEN V. FUTTER AND RICHARD I. BEATTIE - Business relationship |
| Form 990, Part VI, Line 6 Classes of members or stockholders | THE ARTICLES OF INCORPORATION AND BY-LAWS WERE REVIEWED TO DETERMINE THAT THE SUPPORTED ORGANIZATIONS OUTLINED IN SCHEDULE-A HAVE THE POWER TO ELECT OR APPOINT MEMBERS TO THE BOARD OF THE SUPPORTING ORGANIZATIONS. MEMORIAL SLOAN-KETTERING CANCER CENTER, EIN 13-1924236, (MSK), IS THE SINGLE MEMBER OF THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM LLC, PCCTC, WHICH HAS ELECTED TO BE TREATED AS A DISREGARDED ENTITY OF MSK FOR TAX PURPOSES AND MSKCC PROTON, INC. WHICH IS ALSO TREATED AS A CORPORATION FOR TAX PURPOSES. MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES EIN 13-1624082, (MEM), IS THE SINGLE MEMBER OF MSKCC PROPERTIES LLC, WHO HAS ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | PRIOR TO FILING THE RETURN, A REVIEW OF THE 990 WAS CONDUCTED BY THE SR. VP OF FINANCE AND THE CHIEF FINANCIAL OFFICER. IT IS THEN PRESENTED TO, AND REVIEWED BY, THE JOINT AUDIT COMMITTEE OF THE BOARD. THE JOINT AUDIT COMMITTEE REFERS THE FORM 990 TO THE FULL BOARD, AND A COPY IS PROVIDED TO EACH BOARD MEMBER FOR FURTHER REVIEW. MEMORIAL SLOAN-KETTERING'S FORM 990 IS REVIEWED BY COUNSEL AND IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. |
| Form 990, Part VI, Line 12c Conflict of interest policy | IN 2023, MSK'S CONFLICT OF INTEREST (COI) PROGRAM WAS IMPLEMENTED THROUGH THREE COMPREHENSIVE POLICIES FOR MEMORIAL SLOAN KETTERING CANCER CENTER, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, WHICH ARE OUTLINED BELOW: 1. CONFLICT OF INTEREST AND COMMITMENT POLICY (THE "INDIVIDUAL COIPOLICY"). A. THE INDIVIDUAL COI POLICY APPLIED TO: (I) PHYSICIANS AND SCIENTISTS WITH ACADEMIC APPOINTMENTS AT ANY LEVEL; (II) ANY CLINICAL PROVIDER WHO COULD INDEPENDENTLY WRITE ORDERS OR PRESCRIPTIONS; (III) INDIVIDUALS WHOSE ROLES INCLUDED THE DESIGN, CONDUCT OR REPORTING OF RESEARCH AND/OR WERE ENGAGED IN HUMAN SUBJECT RESEARCH; (IV) ADMINISTRATIVE EMPLOYEES WITH INDEPENDENT AUTHORITY TO MAKE PURCHASING DECISIONS OR WHO WERE OTHERWISE ABLE TO BIND, NEGOTIATE ON BEHALF, OR EXECUTE AGREEMENTS ON BEHALF OF, MSK; AND (V) INDIVIDUALS THAT SERVED ON MSK INSTITUTIONAL COMMITTEES WITH RESPONSIBILITY FOR OVERSIGHT OF RESEARCH, FORMULARY, OR PURCHASING DECISIONS. B. MSK'S COMPLIANCE COI OFFICE ("COMPLIANCE") AND THE INSTITUTIONAL CONFLICT OF INTEREST COMMITTEE (THE "MSK COI COMMITTEE") WERE RESPONSIBLE FOR THE ADMINISTRATION OF THIS POLICY, UNDER THE OVERSIGHT OF THE COMMITTEE OF THE BOARD (THE "BOARD COI COMMITTEE") DEDICATED EXCLUSIVELY TO DISCHARGING THE BOARD'S RESPONSIBILITY AND AUTHORITY OVER MSK'S CONFLICTS OF INTEREST PROGRAM. C. UPON BECOMING COVERED BY THE INDIVIDUAL COI POLICY, ANNUALLY THEREAFTER AND/OR AS NEW SIGNIFICANT INTERESTS AROSE, AN INDIVIDUAL WAS REQUIRED TO DISCLOSE FINANCIAL INTERESTS AND EXTERNAL RELATIONSHIPS AND ACTIVITIES ("INTERESTS"), WHETHER PAID OR UNPAID, THAT REASONABLY APPEARED TO BE RELATED TO THE INDIVIDUAL'S INSTITUTIONAL RESPONSIBILITIES. COVERED PERSONS WERE REQUIRED TO DISCLOSE INTERESTS FOR THEMSELVES AND IMMEDIATE FAMILY MEMBERS. D. DEPENDING ON THE CIRCUMSTANCES AND BASED ON ESTABLISHED CRITERIA, DISCLOSED INTERESTS WERE REVIEWED BY COMPLIANCE, THE MSK COI COMMITTEE, MSK COI COMMITTEE DESIGNEE(S), AND/OR THE BOARD COI COMMITTEE TO DETERMINE WHETHER AN INDIVIDUAL CONFLICT OF INTEREST EXISTED OR PRESENTED THE PERCEPTION THEREOF (I.E. WHETHER AN INDIVIDUAL FINANCIAL INTEREST COULD DIRECTLY AND SIGNIFICANTLY IMPACT AN INDIVIDUAL'S INSTITUTIONAL RESPONSIBILITIES, OR AN INDIVIDUAL'S INTEREST COULD BE DIRECTLY AND SIGNIFICANTLY IMPACTED BY THEIR INSTITUTIONAL RESPONSIBILITIES). E. THE POLICY REQUIRED ANY INDIVIDUAL CONFLICT OF INTEREST TO BE MANAGED, REDUCED OR ELIMINATED. WHEN A CONFLICT OF INTEREST DETERMINATION WAS MADE, THE MSK COI COMMITTEE, THE MSK COI COMMITTEE DESIGNEE(S), OR THE BOARD COI COMMITTEE, AS APPLICABLE, DETERMINED HOW TO ADDRESS IT. FOR THOSE CONFLICTS DEEMED MANAGEABLE, MANAGEMENT STRATEGIES IMPLEMENTED INCLUDED DISCLOSURE OF THE INTEREST IN RELEVANT PUBLICATIONS, PRESENTATIONS, CONSENT FORMS, AND EDUCATIONAL MATERIALS; RECUSAL AND/OR OTHER LIMITATION ON ROLE; INDEPENDENT OVERSIGHT BY A DISINTERESTED SENIOR PERSONNEL MEMBER OR COMMITTEE; AND TEMPORARY OR PERMANENT REDUCTION, DIVESTITURE, RELINQUISHMENT, OR TERMINATION OF AN INDIVIDUAL'S INTEREST. 2. INSTITUTIONAL CONFLICT OF INTEREST POLICY (THE "INSTITUTIONAL COI POLICY"). A. THE INSTITUTIONAL COI POLICY APPLIED TO FINANCIAL INTERESTS AND RELATIONSHIPS ("INTERESTS") HELD BY MSK AS AN INSTITUTION, AS WELL AS THOSE FINANCIAL INTERESTS AND RELATIONSHIPS ("INTERESTS") HELD BY SENIOR EXECUTIVE OFFICERS DEEMED "INSTITUTIONAL OFFICIALS, THEIR IMMEDIATE FAMILY MEMBERS. B. INSTITUTIONAL INTERESTS HELD BY MSK WERE MADE AVAILABLE TO COMPLIANCE THROUGH REGULAR REPORTS FROM AND ONGOING ENGAGEMENT WITH RELEVANT MSK DEPARTMENTS. INSTITUTIONAL INTERESTS HELD BY INSTITUTIONAL OFFICIALS WERE DISCLOSED THROUGH THE PROCESS DESCRIBED ABOVE IN THE INDIVIDUAL COI POLICY, AS WELL AS THE PROCESS DESCRIBED BELOW IN THE BOARD COI POLICY. C. THE MSK COI COMMITTEE OR MSK COI COMMITTEE DESIGNEE(S) WERE RESPONSIBLE FOR DETERMINING WHETHER AN INSTITUTIONAL CONFLICT OF INTEREST EXISTED; I.E. WHETHER THE INSTITUTIONAL INTEREST HELD BY MSK OR AN INSTITUTIONAL OFFICIAL (OR THEIR IMMEDIATE FAMILY MEMBERS) COULD, OR COULD REASONABLY BE PERCEIVED TO, DIRECTLY AND SIGNIFICANTLY AFFECT THE DESIGN, CONDUCT, REPORTING, REVIEW, OR OVERSIGHT OF MSK RESEARCH OR THE OUTCOME OF AN MSK ACTIVITY OR DECISION. D. THE POLICY REQUIRED ANY INSTITUTIONAL CONFLICT OF INTEREST TO BE MANAGED, REDUCED OR ELIMINATED. WHEN AN INSTITUTIONAL CONFLICT OF INTEREST DETERMINATION WAS MADE, THE MSK COI COMMITTEE AND/OR THE MSK COI COMMITTEE DESIGNEE(S) DETERMINED HOW TO ADDRESS IT. FOR THOSE CONFLICTS DEEMED MANAGEABLE, MANAGEMENT STRATEGIES IMPLEMENTED INCLUDED RECUSAL OF THE APPLICABLE INSTITUTIONAL OFFICIAL FROM DECISION-MAKING REGARDING THE ARRANGEMENT AND DISCLOSURE TO RELEVANT PERSONNEL; DISCLOSURE OF THE INTEREST IN RELEVANT PUBLICATIONS, PRESENTATIONS, CONSENT FORMS, AND EDUCATIONAL MATERIALS; INDEPENDENT OVERSIGHT BY A DISINTERESTED SENIOR PERSONNEL MEMBER OR COMMITTEE; AND TEMPORARY OR PERMANENT REDUCTION, DIVESTITURE, RELINQUISHMENT, OR TERMINATION OF MSK'S OR AN INSTITUTIONAL OFFICIAL'S INSTITUTIONAL INTEREST. 3. BOARDS OF GOVERNING TRUSTEES CONFLICT OF INTEREST POLICY (THE "BOARD COI POLICY"). A. THE BOARD COI POLICY APPLIED TO BOARD MEMBERS, OFFICERS, AND OTHER MSK SENIOR LEADERSHIP. INDIVIDUALS COVERED BY THE BOARD COI POLICY WERE REQUIRED TO DISCLOSE FINANCIAL INTERESTS AND RELATIONSHIPS, AS DEFINED BY THE POLICY, ANNUALLY AND ON AN ONGOING BASIS. OTHER ENTITIES IN THE SAME TAX-EXEMPT GROUP HAD OVERLAPPING OFFICERS AND BOARD MEMBERS AS DESCRIBED IN SCHEDULE O; SUCH PERSONS REPORTED FINANCIAL INTERESTS THROUGH THIS OR RELATED PROCESSES. B. THE BOARD COI COMMITTEE WAS RESPONSIBLE FOR DETERMINING WHETHER ANY INTEREST DISCLOSED UNDER THE BOARD COI POLICY GAVE RISE TO A CONFLICT OF INTEREST. THE POLICY REQUIRED THAT THE MEMBERS OF THE BOARD COI COMMITTEE VOTE, WITHOUT THE INDIVIDUAL WITH THE POTENTIAL CONFLICT PRESENT, TO DETERMINE WHETHER A CONFLICT OF INTEREST EXISTED. ALL MEMBERS PARTICIPATING IN THE VOTE WERE REQUIRED TO BE DISINTERESTED WITHRESPECT TO THE TRANSACTION, ARRANGEMENT, OR RELATIONSHIP. C. THE COVERED INDIVIDUAL WITH THE CONFLICT OF INTEREST COULD MAKE A PRESENTATION TO THE BOARD COI COMMITTEE, BUT COULD NOT PARTICIPATE IN OR INFLUENCE THE DISCUSSION OF, OR VOTE ON, THE PROPOSED TRANSACTION, ARRANGEMENT, OR RELATIONSHIP. THE EXISTENCE AND RESOLUTION OF ANY CONFLICT OF INTEREST, ALONG WITH ASSOCIATED DETERMINATIONS MADE AND VOTES TAKEN, WERE REQUIRED TO BE DOCUMENTED IN WRITING. D. FOR ANY TRANSACTION, ARRANGEMENT, OR RELATIONSHIP THAT INVOLVED A CONFLICT OF INTEREST, A CONFLICT MANAGEMENT PLAN COULD BE IMPLEMENTED IF DOING SO WAS IN THE BEST INTERESTS OF MSK. MANAGEMENT PLANS COULD REQUIRE DISCLOSURE, RECUSAL OR OTHER LIMITATION OF ROLE, INDEPENDENT OVERSIGHT AND CONFIDENTIALITY. |
| Form 990, Part VI, Line 19 Required documents available to the public | THE INSTITUTION HAS ENGAGED DAC BOND AS OUR INVESTOR RELATIONS AND DISCLOSURE/DISSEMINATION AGENT. COPIES OF OUR IRS FORM 990, 990T AND OUR AUDITED FINANCIAL STATEMENTS, QUARTERLY UNAUDITED FINANCIAL STATEMENTS, AND THE BOND OFFERING STATEMENTS FOR ALL OUR DEBT ISSUES ARE AVAILABLE ON THEIR WEB ADDRESS: WWW.DACBOND.COM. THE CONFLICT OF INTEREST AND COMMITMENT POLICY IS ACCESSIBLE ON OUR INSTITUTIONAL WEB SITE: WWW.MSKCC.ORG. HOWEVER, OUR GOVERNING DOCUMENTS SUCH AS THE ARTICLES OF INCORPORATION AND CORPORATE BY-LAWS ARE NOT AVAILABLE FOR PUBLIC INFORMATION. |
| Form 990, Part VII, Section A Board Member Listing | THIS IRS FORM 990 IS FILED UNDER GROUP EXEMPTION NUMBER 3475, EIN 91-2154267. THE ATTACHED LIST REPRESENTS MEMBERS FROM THE GOVERNING BOARDS OF THE FOLLOWING AFFILIATED INSTITUTIONS THAT MAKE UP OUR EXEMPT GROUP: MEMORIAL SLOAN-KETTERING CANCER CENTER (MSK) EIN 13-1924236, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (MEM) EIN 13-1624082, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (SKI) EIN 13-1624182, S.K.I. REALTY, INC. (SKR) EIN 13-3389586, LOUIS V. GERSTNER JR. GRADUATE, SCHOOL OF BIOMEDICAL SCIENCES (SKG) EIN 20-2212588, MSK INSURANCE US, INC. (MSKI) EIN 83-0363317, AND MSKCC PROTON INC.,(MSKP) EIN 35-2397819. ALSO INCLUDED IN THE GROUP IS MSK PROPERTIES LLC. EIN 35-2464610 WITH MEMORIAL HOSPITAL BEING THE SOLE MEMBER. MEMORIAL SLOAN KETTERING BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK, VICE CHAIR OF THE BOARD STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER, RETIRED 10/23 STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS, VICE CHAIR OF THE BOARD JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D. SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART, CHAIR OF THE BOARD SELWYN M VICKERS, M.D., BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER. EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III, HONORARY CHAIR OF THE BOARD PETER A. WEINBERG 30 TOTAL BOARD MEMBERS; 29 INDEPENDENT BOARD MEMBERS MEMORIAL HOSPITAL BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE, HONORARY CHAIRMAN OF THE BOARD IAN COOK, CHAIR OF THE BOARD STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER, RETIRED 10/23 STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D. SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART SELWYN M VICKERS, MD, BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG 30 TOTAL BOARD MEMBERS; 29 INDEPENDENT BOARD MEMBERS SLOAN KETTERING INSTITUTE BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER, RETIRED 10/23 STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR., HONORARY CHAIR OF THE BOARD JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS, CHAIR OF THE BOARD JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART SELWYN M VICKERS, MD. BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG 30 TOTAL BOARD MEMBERS; 29 INDEPENDENT BOARD MEMBERS S.K.I. REALTY BOARD OF DIRECTORS: RICHARD I. BEATTIE LOUIS V. GERSTNER, JR. JAMES G. NIVEN, PRESIDENT CLIFTON S. ROBBINS SCOTT M. STUART, CHAIRMAN OF THE BOARD DOUGLAS A. WARNER III 6 TOTAL BOARD MEMBERS; 6 INDEPENDENT BOARD MEMBERS GERSTNER GRADUATE SCHOOL BOARD OF TRUSTEES: GEOFFREY CANADA RICHARD I. BEATTIE ELLEN V. FUTTER LOUIS V. GERSTNER, JR., CHAIR EMERITUS MARIE-JOSEE KRAVIS ALAN D SCHNITZER, CHAIR OF THE BOARD SCOTT M. STUART SELWYN M VICKERS MD, BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER 8 TOTAL BOARD MEMBERS; 7 INDEPENDENT BOARD MEMBERS MSK INSURANCE U.S. BOARD OF DIRECTORS: DEBRA BERNS, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER STEPHEN C. SHERRILL, CHAIRMAN OF THE BOARD JEFFREY P. JOHNSON, BOARD MEMBER AND VICE PRESIDENT MICHAEL P HARRINGTON, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER KATHRYN MARTIN (UNTIL 3/23) MARK SVENNINGSON (UNTIL 2/23) MARGARET BURKE (UNTIL 10/23) 4 TOTAL BOARD MEMBERS; 2 INDEPENDENT BOARD MEMBERS MSKCC PROTON INC., BOARD OF DIRECTORS: SIMON POWELL MD., EMPLOYEE, NOT AN INDEPENDENT DIRECTOR MICHAEL HARRINGTON, EMPLOYEE, NOT AN INDEPENDENT DIRECTOR SHELLY ANDERSON, EMPLOYEE NOT A INDEPENDENT DIRECTOR 3 TOTAL DIRECTORS; 0 INDEPENDENT DIRECTORS |
| Form 990, Part VII, Section B, Line 1 INDEPENDENT CONTRACTORS | AMOUNTS PAID TO INDEPENDENT CONTRACTORS INCLUDE AMOUNTS PAID TO SUBCONTRACTORS AS WELL AS REIMBURSABLE EXPENSES. |
| Form 990, Part VIII, Line 11d Other Miscellaneous Revenue | MISC. - Total Revenue: 22468541, Related or Exempt Function Revenue: , Unrelated Business Revenue: 19282934, Revenue Excluded from Tax Under Sections 512, 513, or 514: 3185607; |
| Form 990, Part XI, Line 9 Other changes in net assets or fund balances | Postretirement - -36718000; Other - 1435398; |
| Schedule C, Part II-B | THE ORGANIZATION ENGAGES IN FEDERAL, STATE, AND LOCAL LOBBYING. THE CENTER'S FEDERAL LOBBYING EFFORT FOCUSES ON PATIENT CARE AND REIMBURSEMENT ISSUES. PATIENT CARE ADVOCACY INCLUDES ENSURING PATIENTS ARE ABLE TO ACCESS CLINICAL TRIALS AND CANCER HOSPITALS ARE ABLE TO EFFECTIVELY RESEARCH POTENTIAL TREATMENTS FOR CANCER AS WELL AS PREVENTATIVE AND PALLIATIVE MEASURES. THE CENTER ALSO SEEKS EQUITABLE REIMBURSEMENT FOR SERVICES RENDERED TO PATIENTS ENROLLED IN ENTITLEMENT PROGRAMS. FROM TIME TO TIME, THE CENTER WEIGHS IN ON OTHER FEDERAL LEGISLATION THAT IMPACTS CANCER CARE AND HOSPITALS IN GENERAL. THE CENTER'S STATE LOBBYING EFFORTS FOCUS ON ISSUES RELATING TO PATIENT CARE, PUBLIC HEALTH, AND HOSPITAL OPERATIONS. PATIENT CARE AND PUBLIC HEALTH ISSUES MAY INCLUDE ACCESS TO CARE AND CANCER PREVENTION AND SCREENING, INCLUDING AS PART OF STATE BUDGET LEGISLATION. OUR ADVOCACY ON HOSPITAL OPERATIONS CENTERS ON ISSUES RELATING TO PROFESSIONAL LICENSURE AND CONTINUING EDUCATION, SCOPE OF PRACTICE, HOSPITAL STAFFING, AND HEALTH AND SAFETY REQUIREMENTS. ON OCCASION, THE CENTER ENGAGES IN LOCAL LOBBYING ON ISSUES RANGING FROM BUILDING ORDINANCES TO RADIATION CONTROL. THE CENTER ALSO INCURS COSTS FOR FEDERAL, STATE, AND LOCAL LOBBYING BY ASSOCIATIONS AND OTHER ORGANIZATIONS OF WHICH IT IS A MEMBER. |
| Schedule F, Part V FOREIGN GRANTS AND INVESTMENTS | MSKCC DOES NOT MAKE GRANTS OR USE GRANT MONEY OUTSIDE OF THE UNITED STATES. ALL OF THE VALUES LISTED ARE AT COST, WITH THE EXCEPTION OF THE INVESTMENTS, WHICH ARE VALUED AT FAIR MARKET VALUE. |
| Dissolution The Ralph Lauren Center for Cancer Care and Prevention | Ralph Lauren Center for Cancer Care and Prevention (RLC), EIN: 32-0577172, a charitable corporation organized in New York, had an effective date of dissolution on October 12, 2022 as confirmed by the New York State Department of State. RLC provided dissolution documents to the state of New York during the tax-year ending December 31, 2022. Confirmation of "inactive" status was not provided by the state of New York until May 9, 2023. The "inactive" status, or effective date of dissolution, was noted by the state of New York to be October 12, 2022, which represented the date the dissolution documents were provided to New York. The dissolution of RLC is being reported on with the 2023 Form 990 which represents the year in which confirmation of the dissolution was provided by the state of New York. All of RLC's assets were transferred to Memorial Hospital for Cancer and Allied Diseases (MEM), a related Section 501(c)(3) organization, on March 31, 2019. RLC's transfer of assets to MEM included Cash ($1,004,179), Patient Services Receivable ($27,094), Prepaid Expenses ($35,895, Security Deposit ($44,083) and Property and Equipment ($8,542). Upon dissolution, no officer, director, trustee, or key employee of the organization (1) became or will become a director or trustee of a successor or transferee organization, (2) became or will become an employee of, or independent contractor for, a successor or transferee organization, (3) became or will become a direct or indirect owner of a successor or transferee organization, or (4) received, or became entitled to, compensation or other similar payments as a result of the RLC's liquidation, termination, or dissolution. At the time of dissolution, the organization distributed its assets in accordance with its governing instruments and notified the state of New York, which provided confirmation on May 9, 2023 of retroactive "inactive status", the effective date of dissolution, of October 12, 2022. RLC discharged all of its liabilities in accordance with state law and did not have any tax-exempt bonds outstanding during the year. |
| Software ID: | 23017437 |
| Software Version: | 2023v5.1 |